Editors' note: This article discusses one or more penny stocks and/or microcaps. Such stocks are easily manipulated; do your own careful due diligence.
Company: CKD Bio Corporation
Bloomberg ticker: 063160 KS
Market cap: US$236m
Background: CKD Bio Corporation manufactures raw material medicine. Its products include potassium clavulanate, demeclocycline, rifampicin, and acarbose. CKD Bio is headquartered in Seoul, Korea.
World Class Benchmarking of CKD Bio Corporation
(Click on image to enlarge)
- Profitable Growth rank of 2 was up compared to the prior period’s 4th rank
- This is World Class performance compared to 590 small Health Care companies worldwide
- Profitability rank of 3 was worse than its Growth rank of 2
- Profitability rank of 3 was the same compared to the prior period’s 3rd rank
- This is above average performance compared to peers
- Growth rank of 2 was up compared to the prior period’s 7th rank
- This is World Class performance compared to peers
Comments
Log in or sign up to join the conversation.